The Therapeutic Goods
Administration and Aimedics have
recalled all units of the HypoMon
sleep-time hypoglycaemic monitor.
HypoMon is used by people with
type 1 diabetes aged 10-25 years to
monitor blood glucose while they
sleep, but unfortunately it has been
identified that HypoMon is not
performing as well as expected.
“The rate of detection of sleeptime
hypoglcaemic episodes is
lower than the rate specified,”
according to a TGA update.
The manufacturer Aimedics is
providing a full refund.
A number of HypoMons have
been funded by the Danii Meads-
Barlow Foundation, which is now
subsidising CGM Dexom G4 devices.The above article was sent to subscribers in Pharmacy Daily's issue from 07 Aug 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Aug 13
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.